Abstract
Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.
Keywords: Hematopoietic stem cells, gene therapy, central nervous system, lysosomal storage disorders, blood-brain-barrier, protein delivery, brain parenchyma, ventricular space
Current Gene Therapy
Title:Genetically-Modified Hematopoietic Stem Cells and their Progeny for Widespread and Efficient Protein Delivery to Diseased Sites: The Case of Lysosomal Storage Disorders
Volume: 12 Issue: 5
Author(s): Alessandra Biffi
Affiliation:
Keywords: Hematopoietic stem cells, gene therapy, central nervous system, lysosomal storage disorders, blood-brain-barrier, protein delivery, brain parenchyma, ventricular space
Abstract: Efficient therapeutic protein delivery is a challenging task in several disease contexts and particularly when the CNS is concerned. Different approaches for brain-directed delivery have been thus far investigated, including direct injection of molecules or of their coding information carried by dedicated vector systems within the brain parenchyma or in the ventricular space, intravenous systemic administration of molecules/vectors modified to target and cross the blood-brainbarrier, and exploitation of allogeneic and/or autologous and genetically modified cells as vehicles for the therapeutic of interest. Among these, we here review one of the most promising approaches based on hematopoietic stem cells, taking advantage of lysosomal storage disorders as representative disease setting.
Export Options
About this article
Cite this article as:
Biffi Alessandra, Genetically-Modified Hematopoietic Stem Cells and their Progeny for Widespread and Efficient Protein Delivery to Diseased Sites: The Case of Lysosomal Storage Disorders, Current Gene Therapy 2012; 12 (5) . https://dx.doi.org/10.2174/156652312802762572
DOI https://dx.doi.org/10.2174/156652312802762572 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Current Neuropharmacology Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design Protein Tyrosine Nitration: Role in Aging
Current Aging Science Complementary Peptide Epitopes and Antiidiotypic Antibodies in Autoimmunity
Protein & Peptide Letters Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Up-Regulation of Gr1+CD11b+ Population in Spleen of Dextran Sulfate Sodium Administered Mice Works to Repair Colitis
Inflammation & Allergy - Drug Targets (Discontinued) Curcumin: the Yellow Molecule with Pleiotropic Biological Effects
Letters in Drug Design & Discovery The Role of Adenosine in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bridged Piperazines and Piperidines as CCR1 Antagonists with Oral Activity in Models of Arthritis and Multiple Sclerosis
Letters in Drug Design & Discovery The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets The Antioxidants and Pro-Antioxidants Network: An Overview
Current Pharmaceutical Design Angiopoietin-1 and C16 Peptide Attenuate Vascular and Inflammatory Responses in Experimental Allergic Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Peroxisome Proliferator-Activated Receptor Agonists as Potential Therapeutic Agents in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research A Translational View of Peptide Treatment of Neurological Disorders
Current Medicinal Chemistry